OCUL Share Price Performance
US$0
-13.05 (-100.00%)
Price US$0
Fair ValueUS$27.09
Share Pricen/a
Narrative Update • Aug 20
Ocular Therapeutix, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
OCUL Community Narratives
AN
Fair Value
·Fair Value US$27.09 57.7% undervalued intrinsic discount
OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$18 36.3% undervalued intrinsic discount
Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$34 66.3% undervalued intrinsic discount
Aging Global Trends And Novel Delivery Will Expand Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Ocular Therapeutix
57.7% undervalued intrinsic discount
OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
View narrativeAN
Updated 20 Aug
Ocular Therapeutix
66.3% undervalued intrinsic discount
Aging Global Trends And Novel Delivery Will Expand Markets
View narrativeAN
Updated 23 Jun
Ocular Therapeutix
36.3% undervalued intrinsic discount
Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
View narrativeAN
Updated 14 Apr
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
OCUL: FDA Alignment And Easing Competition Will Drive Future Retinal Upside
Fair Value: US$27.09 57.7% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OCUL: FDA Alignment On Wet AMD NDA Will Drive Bullish Repricing
Fair Value: US$34 66.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OCUL: SOL-1 Phase 3 Data Will Drive Bullish Repricing
Fair Value: US$18 36.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ocular Therapeutix, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.37
- -342.26%
- -579.09%
- 14.0%
About OCUL
- Founded
- 2006
- Employees
- 325
- CEO
- WebsiteView website
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
